Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Edgewise Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 220,000 options to buy @ $7.08, valued at $1.6M
08/18/2023 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 133,333 options to buy @ $7.08, valued at $944k
08/18/2023 4 Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 600,000 options to buy @ $7.08, valued at $4.2M
05/03/2023 4 Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,747 shares @ $8.9049, valued at $15.6k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,897 shares @ $8.9049, valued at $16.9k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,336 shares @ $8.9049, valued at $11.9k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,602 shares @ $8.9049, valued at $14.3k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 3,254 shares @ $8.9049, valued at $29k
Exercised 10,416 restricted stock units @ $0
05/03/2023 4 KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 3,203 shares @ $8.9049, valued at $28.5k
Exercised 10,416 restricted stock units @ $0
03/07/2023 4 Fox Jonathan C (Director) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 43,731 options to buy @ $9.43, valued at $412.4k
03/07/2023 3 Fox Jonathan C (Director) has filed a Form 3 on Edgewise Therapeutics, Inc.
01/03/2023 4 Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 300,000 options to buy @ $8.94, valued at $2.7M
10/05/2022 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 4,730 shares @ $9.7579, valued at $46.2k
Exercised 4,730 options to buy @ $1.93, valued at $9.1k
09/16/2022 4 Thompson Peter A. (10% Owner) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Bought 484,496 shares @ $10.32, valued at $5M
09/16/2022 4 ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Bought 484,496 shares @ $10.32, valued at $5M
09/16/2022 4 Novo Holdings A/S (10% Owner) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Bought 484,496 shares @ $10.32, valued at $5M
09/08/2022 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 2,379 shares @ $10.8262, valued at $25.8k
Sold 2,351 shares @ $10.992, valued at $25.8k
Exercised 4,730 options to buy @ $1.93, valued at $9.1k
08/10/2022 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $10.39, valued at $2.1M
08/10/2022 4 Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 220,000 options to buy @ $10.39, valued at $2.3M
08/10/2022 4 Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $10.39, valued at $2.1M
08/10/2022 4 Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $10.39, valued at $2.1M
08/10/2022 4 Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 240,000 options to buy @ $10.39, valued at $2.5M
08/10/2022 4 KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 550,000 options to buy @ $10.39, valued at $5.7M
08/05/2022 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 9,232 shares @ $9.3069, valued at $85.9k
Exercised 4,730 options to buy @ $1.93, valued at $9.1k
Exercised 4,502 options to buy @ $0.71, valued at $3.2k
07/07/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/28/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/28/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/28/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/28/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy